July 28, 2015 BY EMAIL Craig E. Fraser Dear Craig:Severance Agreement • March 15th, 2016 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
As we have discussed, your employment with Aegerion Pharmaceuticals, Inc. (the “Company”) has terminated effective as of July 26, 2015 (the “Separation Date”). The purpose of this letter agreement (the “Agreement”) is to confirm the agreement between you and the Company concerning your separation from employment and severance benefits, as follows:
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • March 15th, 2016 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment No. 1 to Employment Agreement (this “Amendment”), is entered into as of November 5, 2015, by and between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Gregory Perry (the “Employee”).
FIRST AMENDMENT TO FORBEARANCE AGREEMENTForbearance Agreement • March 15th, 2016 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO FORBEARANCE AGREEMENT (this “Amendment”) is made as of this 7th day of December, 2015 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”) and AEGERION PHARMACEUTICALS, INC., a Delaware corporation with its chief executive office located at One Main Street, 8th Floor, Cambridge, Massachusetts 02142 (“Borrower”).
ContractForbearance Agreement • March 15th, 2016 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS FORBEARANCE AGREEMENT (this “Agreement”) made as of this 9th day of November, 2015 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”) and AEGERION PHARMACEUTICALS, INC., a Delaware corporation with its chief executive office located at One Main Street, 8th Floor, Cambridge, Massachusetts 02142 (“Borrower”).
SECOND AMENDMENT TO FORBEARANCE AGREEMENTForbearance Agreement • March 15th, 2016 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS SECOND AMENDMENT TO FORBEARANCE AGREEMENT (this “Amendment”) is made as of this 7th day of January, 2016 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”) and AEGERION PHARMACEUTICALS, INC., a Delaware corporation with its chief executive office located at One Main Street, 8th Floor, Cambridge, Massachusetts 02142 (“Borrower”).
THIRD AMENDMENT TO FORBEARANCE AGREEMENTForbearance Agreement • March 15th, 2016 • Aegerion Pharmaceuticals, Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT TO FORBEARANCE AGREEMENT (this “Amendment”) is made as of this 26th day of February, 2016 by and between SILICON VALLEY BANK, a California corporation, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at 275 Grove Street, Suite 2-200, Newton, Massachusetts 02466 (“Bank”) and AEGERION PHARMACEUTICALS, INC., a Delaware corporation with its chief executive office located at One Main Street, 8th Floor, Cambridge, Massachusetts 02142 (“Borrower”).
